|Last Price$85.46||Day Change (%)2.74%|
|Open Price$85.66||Day Change ($)2.28|
|Day Range81.80–86.35||52-Week Range55.95–86.35|
As of Thu 04/17/2014 03:44 PM EST | USD
Good morning, and welcome to the First Quarter 2014 Dover Corporation Earnings Conference Call. With us today are Bob Livingston, President and Chief Executive Officer; Brad Cerepak, Senior Vice President and CFO; and Paul Goldberg, Vice President of Investor Relations.
On Monday, Neurocrine Biosciences NBIX accelerated its anticipated filing date for indiplon capsules to the second quarter of 2007 instead of 2009. We're placing Neurocrine under review while we revisit our assumptions, and because DOV Pharmaceutical DOVP is entitled to a royalty on any indiplon ...
Industrial activity remains slow and steady, giving companies a chance to navigate the environment.
We like 3-D printer firms' growth fundamentals, but current valuations limit long-term investor returns.
Widening investment-grade credit spreads and rising interest rates lead to losses.
A number of technical factors in the municipal bond market have magnified the selling pressure.